Biostage, Inc. (NASDAQ: BSTG) is pioneering radically new
technologies for the development of bioengineered organ implants targeting
cancer and other life-threatening diseases of the esophagus, bronchus, and
trachea. Traditional treatment options for such diseases are limited, with
significant risk of complications and negative effect on quality of life. The
company’s Cellframe™ technology uses the patient’s own stem cells to seed onto
a proprietary biocompatible scaffold designed to guide the regeneration of a
biological structure matching the dimensions of the organ being regenerated.
The resulting organ-specific “Cellspan” implants represent a unique
personalized approach to organ regeneration.
Biostage has worked long to evolve their revolutionary Cellframe™
technology, which, in the company’s words, “combines the best attributes of a
synthetic scaffold with tissue engineering and cell biology,” creating a
platform representing “a complete re-engineering” of their earlier organ
scaffold and cell technology. In May 2016, Biostage announced successful
results from large-animal studies of their Cellspan Esophageal Implant,
conducted in conjunction with Mayo Clinic, and the company is in the process of
getting these results published in a peer-reviewed scientific journal, an
important step toward full recognition. The company plans to file an
investigational new drug application (IND) with the U.S. Food and Drug
Administration (FDA), and it expects to conduct human clinical trials in 2017.
The goal of these clinical trials is to demonstrate the technology’s superior
mortality rates, with reduced complications and improved quality of life for
patients.
The company’s stated values are based upon its management
team’s belief that its proprietary Cellframe technology has the “opportunity to
dramatically advance the field of regenerative medicine by improving the
treatment options for patients with life-threatening conditions,” with an
overall target of “breakthrough solutions for unmet medical needs.”
The Chief Executive Officer of Biostage, Jim McGorry, has
over 30 years of leadership experience with a number of companies in the
medical and biotech industries, in addition to carrying an MBA with a
concentration in healthcare from Duke University, and a BS in Engineering from
West Point. He also served as an officer in the United States Army for six
years, including commanding a special operations Green Beret SCUBA detachment.
For more on Biostage, visit www.biostage.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
